BIFACTORIAL ENDOSPERM BOX, TRANS-ACTIVATING FACTOR THAT BINDS THERETO, AND METHOD OF REGULATION OF PROMOTER ACTIVITY

Details for Australian Patent Application No. 2002331395 (hide)

Owner MERISTEM THERAPEUTICS SA

Inventors NORRE, Frederic; GRUBER, Veronique

Pub. Number AU-A-2002331395

PCT Number PCT/EP02/08721

PCT Pub. Number WO2003/014349

Priority 01 118 967.7 06.08.01 EP

Filing date 5 August 2002

Wipo publication date 24 February 2003

International Classifications

C12N 015/29 Mutation or genetic engineering - Genes encoding plant proteins, e.g. thaumatin

C12N 005/10 Undifferentiated human, animal or plant cells, e.g. cell lines - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells

C07K 014/415 Peptides having more than 20 amino acids - from plants

A01H 005/00 Products

C12N 015/82 Mutation or genetic engineering - for plant cells

Event Publications

6 February 2003 Complete Application Filed

  Priority application(s): 01 118 967.7 06.08.01 EP

19 June 2003 Application Open to Public Inspection

  Published as AU-A-2002331395

6 May 2004 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(f)/See Reg. 8.3(3). Examination has not yet been requested or directed for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2002331396-HIGH-STRENGTH, HIGH-DUCTILITY NODULAR IRON, AND TRANSMISSION HOUSING PRODUCED THEREFROM

2002331394-3-ARYLSULFONYL-7-PIPERAZINYLINDOLES, -BENZOFURANS AND - BENZOTHIOPHENES WITH 5-HT6 RECEPTOR AFFINITY FOR TREATING CNS DISORDERS